With further advances in our understanding of protease functions, origin, temporal release, and properties coupled with improvements in protein engineering, we expect that other therapeutic cysteine protease inhibitors will gain regulatory approval for use in the early stages of breast cancer [56–58]. Here, CTSB is linked to breast carcinoma.